TY - JOUR
T1 - Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma
T2 - CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas
AU - Tang, Ling-Long
AU - Huang, Cheng-Long
AU - Lin, Shao-Jun
AU - Le, Quynh-Thu
AU - O'Sullivan, Brian
AU - Yom, Sue S
AU - Huang, Shao Hui
AU - Chan, Annie W
AU - Lee, Nancy
AU - Pan, Jian-Ji
AU - Mejia, Michael Benedict A
AU - Ahn, Yong Chan
AU - Wong, Kenneth C W
AU - McDowell, Lachlan
AU - Orlandi, Ester
AU - Friborg, Jeppe
AU - Chen, Yu-Pei
AU - Yasuda, Koichi
AU - Kodaira, Takeshi
AU - Whitley, Alexander C
AU - King, Ann D
AU - Prajogi, Gregorius Ben
AU - Hahn, Ezra
AU - Lin, Jin-Ching
AU - Kiyota, Naomi
AU - Lee, Victor
AU - Ji, Peng-Jie
AU - Hitchcock, Ying
AU - Hoebers, Frank
AU - Blanchard, Pierre
AU - Moon, Sung Ho
AU - Wan Ishak, Wan Zamaniah
AU - Harrington, Kevin J
AU - Yang, Kun-Yu
AU - Colevas, A Dimitrios
AU - Lee, Anna
AU - Hu, Chao-Su
AU - Rosenthal, David
AU - Siddiqui, Farzan
AU - Langendijk, Johannes Albertus
AU - Lang, Jin-Yi
AU - Yi, Jun-Lin
AU - Shen, Liang-Fang
AU - Li, Ji-Bin
AU - Liu, Li-Zhi
AU - Lee, Anne W M
AU - Mai, Hai-Qiang
AU - Yang, Ming-Kai
AU - Sun, Ying
AU - Chua, Melvin L K
AU - Ma, Jun
N1 - Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
PY - 2025/9
Y1 - 2025/9
N2 - The Chinese Society for Therapeutic Radiology Oncology, the Chinese Anti-Cancer Association, the Chinese Society of Clinical Oncology, Head and Neck Cancer International Group, the European Society for Radiotherapy and Oncology, and the American Society for Radiation Oncology jointly developed evidence-based guidelines and a contouring atlas for primary target volume delineation for radiotherapy in nasopharyngeal carcinoma. The guidelines systematically address three crucial challenges: margin design of clinical target volumes; target volume delineation after induction chemotherapy; and low-risk clinical target volume delineation based on local stepwise extension patterns. Based on a comprehensive systematic review and critical appraisal by an international multidisciplinary panel of 50 nasopharyngeal carcinoma specialists from 17 countries and regions, these guidelines are in keeping with advances in nasopharyngeal carcinoma diagnosis and treatment, embodying contemporary treatment concepts, and elaborating on the differences in practice. These guidelines aim to support global clinical practice in radiotherapy target volume delineation, substantially enhancing homogeneity and reducing variability in nasopharyngeal carcinoma target delineation.
AB - The Chinese Society for Therapeutic Radiology Oncology, the Chinese Anti-Cancer Association, the Chinese Society of Clinical Oncology, Head and Neck Cancer International Group, the European Society for Radiotherapy and Oncology, and the American Society for Radiation Oncology jointly developed evidence-based guidelines and a contouring atlas for primary target volume delineation for radiotherapy in nasopharyngeal carcinoma. The guidelines systematically address three crucial challenges: margin design of clinical target volumes; target volume delineation after induction chemotherapy; and low-risk clinical target volume delineation based on local stepwise extension patterns. Based on a comprehensive systematic review and critical appraisal by an international multidisciplinary panel of 50 nasopharyngeal carcinoma specialists from 17 countries and regions, these guidelines are in keeping with advances in nasopharyngeal carcinoma diagnosis and treatment, embodying contemporary treatment concepts, and elaborating on the differences in practice. These guidelines aim to support global clinical practice in radiotherapy target volume delineation, substantially enhancing homogeneity and reducing variability in nasopharyngeal carcinoma target delineation.
KW - Humans
KW - Nasopharyngeal Carcinoma/radiotherapy
KW - Nasopharyngeal Neoplasms/radiotherapy
KW - Radiotherapy Planning, Computer-Assisted/standards
KW - Radiation Oncology/standards
UR - http://www.scopus.com/inward/record.url?scp=105014781316&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(25)00327-4
DO - 10.1016/S1470-2045(25)00327-4
M3 - Review
C2 - 40907526
SN - 1470-2045
VL - 26
SP - e477-e487
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 9
ER -